Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).
Centafadine is Otsuka’s drug-candidate that is in late-stage development for the treatment of ADHD and the posters report experimental results from the non-clinical assessment of Centanafadine’s risk for human abuse.
The poster session is scheduled for Monday 16th November at 17.00 – 18.30h (EST) [22.00-23.30h (UK time)].
An investigation of the reinforcing potential of centanafadine in rats trained to self-administer cocaine.
David Heal, Sharon Smith, Harriet Day, Zara Turnbull, Reem Elbekai
An investigation of the discriminative properties of centanafadine in rats trained to discriminate d-amphetamine from saline.
Reem Elbekai, Helen Rowley, David Heal